Trump Signs Executive Order to Expedite Psychedelic Drug Research and Treatments
President Donald Trump signed an executive order to accelerate research and treatments based on psychedelic drugs, aiming to ease restrictions on substances like psilocybin, ibogaine, LSD, and MDMA. The move is expected to impact the psychedelics industry and related biotechnology firms.
Tickers: $ATAI
Topics: government_policy healthcare_regulation psychedelic_drugs